1456 fragments arising from smart
fragmentationof approved drugs
Acknowledged as powerful tool for successful identification of lead series, fragment-based drug design is widely implemented in industry and academia. To meet researchers’ expectations, Prestwick Chemical medicinal chemists have designed a unique collection of 1456 small molecules (MW<300) arising from the smart fragmentation of approved drugs (up to year 2016).
Key features
Good coverage of lead-like diversity space
High-quality hit increased by using fragments derived from approved drugs
Rapid follow-up on primary hits possible
Experimental solubility in DMSO (100 mM) and PBS (1 mM) available
Purity 95%+ (H NMR spectrum and LC/MS available)
Balanced set of Ro3 compliant (55%) and Ro3 non-compliant (45%) fragments – Mean MW: 182
56% are exclusive to the Prestwick Drug-Fragment Library and cannot be found in any other major supplier of fragment libraries
How provided?
| Format | Comments | |
|---|---|---|
| Core set 480 cpds |
|
Representative set of the entire library Ready for Screening Highly recommanded for rapid outcomes |
| Complete library |
|
Available for cherry picking |
| Customized set |
|
Selection based on your own criteria (physicochemical properties, substructure or similary search) |
| Re-supply guaranteed |
Application
- Fragment screening (X-ray crystallography, NMR, SPR, high concentration bioassay, …)
- HTS for small molecules
Request a quote